• Cell Medica to Manufacture WT1-TCR Therapy for Mesothelioma, Other Solid Tumors in 2018
  • Assessing Chemo and Immunotherapy Biomarkers at the Right Time Seen as Crucial in Mesotheliomia Monitoring
  • Mesothelioma Risk Continues to Increase — 40 Years After Exposure
  • Researchers Identify CXCR4 as Weak Therapeutic Target for Pleural Mesothelioma
  • PD-L1-positive Immune Cells May Help to Predict Survival Rates in EPMM, Study Says
  • Combining Immunotherapy, Accelerated Radiation and Surgery Bolsters Immune Response Against Mesothelioma, Study Shows
  • New Way to Promote Cell Death Could Lead to Better Mesothelioma Therapies, Study Reports
  • Zoledronic Acid Could Be a Mesothelioma Add-On Treatment, Researchers Contend After Pilot Study
  • TCR²’s Engineered Immune T-Cells Outperform More Common Class of Cells Against Mesothelioma, Studies Show
  • Chemotherapy Effective in Peritoneal Mesothelioma, But Surgery Also Needs Evaluation, Researchers Say
  • MicroRNAs Help Predict Pleural Mesothelioma Outcomes, European Study Finds
  • Prestigious Publication Highlights 2016 Scientific Advances in Thoracic Oncology